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asymptomatic pediatric IDDM patients. Compared to
other guidelines, this one required prompt initiation,
more frequent eye exams, and earlier ophthalmologist re-
ferrals. OBJECTIVES: The purpose of this study was to
examine the cost-effectiveness of retinopathy screening in
pediatric patients with Type I diabetes under the new
policy. METHODS: Cost-effectiveness model was devel-
oped using Microsoft Excel 7.0, incorporating data from
previous epidemiological studies and clinical trials. Markov
Model was used, combined with sensitivity analysis. RE-
SULTS: Screening in pediatric patients was not only cost-
effective, but was actually cost saving from the societal
perspective. During the first 10 years of IDDM, retinopa-
thy screening was very cost-effective (CER  74$/QALY
at year 5). Starting from the 10th year, the intervention re-
sulted in an increasing level of cost and QALY savings.
The amount of QALY saved and cost savings both peaked
at 15 to 20 years after IDDM onset. Under 100% com-
pliance rate, screening produce average savings of $48,412
and Quality Adjusted Life Year (QALY) saved of 7.15
per patient. Our model was sensitive to the compliance
rate of screening; at 50% compliance rate, the total costs
for detection and treatment increased near 2-fold. Screen-
ing by ophthalmologists instead of primary care physi-
cians reduced the total costs by 53.5%. CONCLUSIONS:
Our analysis indicated that, under the new policy, the pro-
posed program reduced QALY loss, and reduced diabetic
retinopathy disease costs.
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OBJECTIVES: To evaluate the potential of clinical, de-
mographic and utilization factors in predicting treatment
costs for diabetic foot ulcers. METHODS: Retrospective
analysis of administrative outpatient pharmacy and med-
ical claims from 1/96–12/98 was conducted using Proto-
care Science’s Managed Care Database. Diabetic patients
were identified using diagnoses and medication claims.
Diagnosis of chronic skin ulcer of lower limbs defined
foot ulcer. Descriptive analysis of demographic, clinical,
and prior medical resource use information was per-
formed, followed by multivariate regression to estimate
the potential of these variables in explaining foot ulcer
treatment charges. RESULTS: The prevalence of diag-
nosed foot ulcers was 1.4% (2881 of the 212,563 identi-
fied diabetics). Patients with foot ulcers were older (mean
age 64.9 years vs. 60.7 years) and more likely to be male
(59.6% vs. 50%) than the non-foot ulcer diabetic popu-
lation. Diabetes-related complications and comorbidities
were common including skin infections, peripheral vascu-
lar disorders, and neurologic problems. During three
months following onset of foot ulcer, related care repre-
sented 40% of the $2596 average monthly charges per
patient. Using regression, demographic, clinical and prior
resource utilization information explained one-fifth of
the ulcer-related charges (R-square  0.22). Ulcer sever-
ity at onset, previous cellulitis or skin abscess, and pen-
toxifylline use were the strongest contributors. CON-
CLUSIONS: Although claims data cannot fully explain
variations in foot ulcer treatment costs, clinical factors,
such as markers for ulcer severity and active treatment of
peripheral vascular disease are predictors of treatment
costs. The correlation between previous skin problems
and treatment costs was negative, suggesting that height-
ened awareness through past experience may result in
lower treatment costs.
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OBJECTIVE: To compare direct medical costs of the
treatment of type-2 diabetic patients with hypertension,
hyperlipidemia, and no comorbidity. METHODS: The
study used an integrated medical and pharmacy claims
database from the Hawaii Medical Service Association.
Patients with at least one paid medical claim in the calen-
dar year 1995 for type-2 diabetes mellitus were selected.
Subsequently, these patients were segregated into three
mutually exclusive categories: patients with hypertension
as the sole comorbidity (Nhtn), patients with hyperlipi-
demia only (Nhlpd), and patients with no recorded comor-
bidity (Nnoco) in 1995. Average and median total medical
treatment costs as well as medical costs for the treatment
of diabetes and commonly associated comorbidities were
estimated for each population. RESULTS: Table 1 shows
sample size, age and gender distributions of three popula-
tions. Table 2 shows the total medical and diabetes and
associated comorbidity related medical costs of treat-
ment.
Table 1. Demography
Populations Sample size
Age
% femaleAverage Median
Nhtn 808 52 53 51.1
Nhlpd 657 50 51 47.6
Nnoco 623 45 47 52.3
